Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.48 |
| ▸ | SUV39H2 | Q9H5I1 | 7/20 | 0.47 |
| ▸ | NPY2R | P49146 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28595542 | 1.00 | SYK (0.50) | SYKPIM1PIM3PIM2SUV39H2 | |
| SCHEMBL28605703 | 0.94 | SYK (0.51) | SYKPIM1PIM3PIM2NPY2R | |
| SCHEMBL28605705 | 0.94 | SYK (0.51) | SYKPIM1PIM3PIM2NPY2R | |
| SCHEMBL28603234 | 0.89 | SYK (0.50) | SYKPIM1PIM3PIM2CTSK | |
| SCHEMBL28603231 | 0.89 | SYK (0.50) | SYKPIM1PIM3PIM2CTSK | |
| SCHEMBL12283421 | 0.88 | PIM1 (0.52) | SYKPIM1PIM3PIM2SUV39H2 | |
| SCHEMBL12836025 | 0.87 | CTSK (0.50) | SYKPIM1PIM3PIM2SUV39H2 | |
| SCHEMBL18064896 | 0.85 | PIM1 (0.51) | SYKPIM1PIM3PIM2CTSK | |
| SCHEMBL31318667 | 0.84 | SUV39H2 (0.51) | PIM1PIM3PIM2SUV39H2DRD2 | |
| SCHEMBL12836149 | 0.84 | SUV39H2 (0.50) | SYKPIM1PIM3PIM2SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2024-10-08 | — | — | US | disclosed |
| CN-113164461-A | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | SYK 4147/4885PIM1 4753/4885PIM3 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.